BiotechTube

Rituximab + Fludarabine + CAMPTH-1H

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkins Lymphoma

Conditions

Non-Hodgkins Lymphoma

Trial Timeline

Jan 1, 2002 → Apr 1, 2008

NCT ID
NCT00193466

About Rituximab + Fludarabine + CAMPTH-1H

Rituximab + Fludarabine + CAMPTH-1H is a phase 2 stage product being developed by Bayer for Non-Hodgkins Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00193466. Target conditions include Non-Hodgkins Lymphoma.

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00193466Phase 2Completed

Competing Products

15 competing products in Non-Hodgkins Lymphoma

See all competitors
ProductCompanyStageHype Score
Acalabrutinib + ACP-319AstraZenecaPhase 1/2
32
JBH492NovartisPhase 1
21
Glofitamab + Atezolizumab + Obinutuzumab + Tocilizumab + Polatuzumab Vedotin + 89Zr-Df-IAB22M2CRochePhase 1/2
36
Obinutuzumab + Glofitamab + Gemcitabine + OxaliplatinRochePhase 2
42
Cyclophosphamide + Mitoxantrone + Vincristine + Prednisone + RituximabAmgenPhase 2
35
hLL2 (epratuzumab)Gilead SciencesPhase 1
21
Velcade + TemsirolimusPfizerPhase 2
35
alemtuzumabSanofiPhase 1/2
24
Odronextamab + REGN5837Regeneron PharmaceuticalsPhase 1
36
Rituximab + 90Y ibritumomab tiuxetan (Zevalin) + Cyclophosphamide + FludarabineBayerPhase 1/2
25
Rituximab + CHOP + CVP + Ibritumomab TiuxetanBiogenPhase 2
32
Ifosfamide + Carboplatin + Etoposide + Rituximab + 90Y ZevalinBiogenPhase 2
32
UblituximabTG TherapeuticsPhase 1/2
29
Ublituximab + LenalidomideTG TherapeuticsPhase 1
18
XmAb13676XencorPhase 1
23